$COLL News

Collegium Pharmaceutical: Pain Cash Flows Are Funding An ADHD Re-Rating

Collegium Pharmaceutical Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2 Reasons to Sell COLL and 1 Stock to Buy Instead

Assessing Collegium Pharmaceutical (COLL) Valuation After Recent Share Price Weakness

Why Collegium Pharmaceutical Inc. (COLL) Stock Is Gaining Attention for Its ADHD Portfolio

Collegium to Participate in 2026 Jefferies Global Healthcare Conference

Collegium Pharmaceutical’s Q1 Earnings Call: Our Top 5 Analyst Questions

Collegium Pharmaceutical's (NASDAQ:COLL) Solid Earnings Are Supported By Other Strong Factors

Collegium Completes Acquisition of AZSTARYS® from Corium Therapeutics

COLL Q1 Deep Dive: ADHD Portfolio Expansion and Pain Segment Stability Drive Results

Collegium Pharmaceutical, Inc. 2026 Q1 - Results - Earnings Call Presentation

Collegium Pharmaceutical, Inc. Q1 2026 Earnings Call Summary

Collegium (COLL) Q1 2026 Earnings Transcript

Collegium Pharmaceutical Q1 Earnings Call Highlights

Collegium Pharmaceutical, Inc. (COLL) Q1 2026 Earnings Call Transcript

Collegium Pharmaceutical (COLL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Collegium Pharmaceutical (COLL) Q1 Earnings and Revenues Beat Estimates

Collegium Pharmaceutical (NASDAQ:COLL) Surges on Q1 Earnings Beat as JORNAY PM Revenue Jumps 36%

Collegium Pharmaceutical (NASDAQ:COLL) Exceeds Q1 CY2026 Expectations, Stock Soars

Collegium Reports First Quarter 2026 Financial Results and Highlights Recent Company Progress